SynBioBeta

Human genomics is changing drug discovery by helping teams understand disease with greater precision from the start 💊🔍 🧬 SynBioBeta • May 4–7, 2026 • San Jose 📍 Join 2,000+ leaders shaping the future of biotech. Get your tickets to SynBioBeta 2026 before prices go up → Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology

Breakout Ventures has secured $114 million for its Fund III, targeting seed-stage investments in companies harnessing AI to tackle complex scientific challenges. The fund's launch follows notable successes, including the $400 million acquisition of Surf Bio by Halozyme, and initial investments in startups like Reach Industries and a stealth University of Chicago spinout focused on small molecule discovery. businesswire.com/news/home/2026… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

AI is speeding up DNA synthesis in ways that could reshape how biology gets built, tested, and scaled 🧬⚙️🚀 🧬 SynBioBeta • May 4–7, 2026 • San Jose Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology

Ginkgo Bioworks has officially launched Ginkgo Cloud Lab, an innovative platform enabling researchers to conduct experiments via a web browser using the company's autonomous lab infrastructure. This platform features AI-driven compatibility assessments and remote access to over 70 lab instruments, marking a strategic shift toward fully automated R&D services while inviting collaboration from academia and the biopharmaceutical industry. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Better vaccine delivery could mean better outcomes — and lower risk where it matters most 💉❤️🔬 📍SynBioBeta • May 4–7, 2026 • San Jose Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology

Paris-based biotech startup baCta has raised €7 million in Seed funding led by LocalGlobe and Daphni, with aims to scale its AI-driven bioproduction of astaxanthin, an antioxidant used in health and cosmetics. The company plans to leverage its proprietary yeast strain and advanced synthetic biology techniques to achieve competitive unit economics and enhance resilience in the supply chain for industrial ingredients. eu-startups.com/2026/03/paris-… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Generate Biomedicines has priced its shares at $16, successfully raising $400 million in its U.S. IPO, with 25 million shares sold. The company, known for its AI-driven drug discovery platform, focuses on developing protein-based therapies in immunology and oncology, including its lead candidate GB-0895 for severe asthma, currently in late-stage trials. Trading under the ticker "GENB" on Nasdaq begins Friday. reuters.com/business/healt… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

President Trump nominates Jim O’Neill, former HHS deputy secretary and acting CDC director, to lead the National Science Foundation for a six-year term, filling a vacancy that has persisted for nearly 10 months. O’Neill's extensive background in health and science policy positions him to steer the NSF's funding for basic research and education in the U.S. if confirmed by the Senate. executivegov.com/articles/jim-o… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

PlasmaLeap Technologies has raised A$30 million (US$20 million) in Series A funding, led by the Gates Foundation, Investible, and Yara Growth Ventures, to develop innovative fertilizer hubs in New South Wales and Tasmania. Their patented reactor technology enables on-farm production of ammonia and nitric acid using only air, water, and renewable electricity, aiming to significantly reduce agricultural emissions and reliance on traditional supply chains. igrownews.com/plasmaleap-tec… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

GSK has finalized a $950 million cash deal to acquire Canadian biotech 35Pharma, aiming to strengthen its portfolio with the experimental pulmonary hypertension treatment HS235. This acquisition comes as CEO Luke Miels seeks to address patent expirations on key HIV drugs and reinforces GSK's focus on obesity-related health conditions, an increasingly crowded market. reuters.com/legal/transact… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

In a strategic move to enhance its oncology portfolio, Gilead Sciences has agreed to acquire Arcellx for an implied equity value of $7.8 billion, securing full ownership of the late-stage CAR T therapy anitocabtagene autoleucel (anito-cel). This acquisition consolidates Arcellx's innovative D-Domain platform with Gilead's established cell therapy infrastructure, positioning the company to accelerate development and commercialization efforts ahead of the therapy's FDA decision expected by December 2026. news.biobuzz.io/2026/02/23/bre… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Manus has expanded its partnership with the U.S. Department of Health and Human Services, receiving an additional $15 million to enhance domestic production of shikimic acid, a vital component for oseltamivir, the active ingredient in Tamiflu. This funding aims to strengthen U.S. health security by reducing reliance on foreign supply chains, addressing a critical vulnerability, as over 80% of essential medicine ingredients are sourced overseas. manusbio.com/articles/manus… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Turbine has raised $25 million in a Series B round led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and other existing investors. The funding will enhance Turbine's virtual cell platform and support a new partnership with a top 10 pharmaceutical company to model immune cell behavior, aiming to streamline the discovery of novel immunotherapy combinations. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…